Anbio Biotechnology
NNNN
8 hedge funds and large institutions have $1.29M invested in Anbio Biotechnology in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 0 closing their positions.
60% more funds holding
Funds holding: 5 → 8 (+3)
44% more capital invested
Capital invested by funds: $894K → $1.29M (+$396K)
0.05% more ownership
Funds ownership: 0.07% → 0.11% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$245K |
| 2 |
Morgan Stanley
New York
|
+$191K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$91.1K |
| 4 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
+$6.94K |
| 5 |
BFS
Bare Financial Services
Gap,
Pennsylvania
|
+$391 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $662K | – | – | – |
|
|
2
BNP Paribas Financial Markets
Paris,
France
| $267K | +$245K | +9,400 | +940% |
|
|
3
Morgan Stanley
New York
| $189K | +$191K | +7,310 | +26,107% |
|
|
4
UBS Group
Zurich,
Switzerland
| $163K | +$91.1K | +3,490 | +122% |
|
|
EWA
5
EverSource Wealth Advisors
Birmingham,
Alabama
| $6.83K | +$6.94K | +266 | New |
|
6
Wells Fargo
San Francisco,
California
| $2.57K | – | – | – |
|
|
BFS
7
Bare Financial Services
Gap,
Pennsylvania
| $385 | +$391 | +15 | New |
|
|
BTI
8
Blue Trust Inc
Alpharetta,
Georgia
| $128 | +$130 | +5 | New |
|
NNNN Hedge Fund Activity: Q1 2026 in Review
8 of the 8,143 institutional investors tracked by Wall St. Rank reported a position in Anbio Biotechnology (NNNN) for Q1 2026, worth a combined $1.29M — up 44% from $894K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NNNN positions and 0 closed out — a net gain of 3 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $245K.
- 8 institutional investors held Anbio Biotechnology (NNNN) as of Q1 2026, up from 5 in Q4 2025.
- Funds reported $1.29M of Anbio Biotechnology stock for Q1 2026, up 44% quarter-over-quarter.
- 3 funds opened new Anbio Biotechnology positions in Q1 2026 and 0 closed out, a net change of +3 holders.
- The largest Anbio Biotechnology buyer in Q1 2026 was BNP Paribas Financial Markets, an estimated $245K added.
Based on aggregated 13F filings for Q1 2026.